Clinical Trial Update: Study of Idelalisib in Combination With BI 836826 in Participants With Chronic Lymphocytic Leukemia [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating idelalisib in combination with BI 836826 in chronic lymphocytic leukemia has been terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• BI 836826
• Idelalisib (idelalisib)

Snippet

Sponsor: Gilead Sciences | Conditions: Chronic Lymphocytic Leukemia (CLL) | Phase 1 | Status: TERMINATED | Results posted: 2020-11-25